NCT06706570 2026-03-24
PIK3CA Mutational Status Assessment
European Institute of Oncology
Recruiting
Clinical Trials
10 trialsNCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
NCT06616987 2025-08-28
Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
Samsung Medical Center
Phase 2 Recruiting
NCT06966141 2025-05-11
A Real World Study of Sacituzumab Govitecan
Fudan University
Recruiting
NCT06611891 2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3 Recruiting
NCT06718933 2025-02-06
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Fudan University
Phase 1/2 Recruiting
NCT05420779 2024-05-08
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Tasly Pharmaceutical Group Co., Ltd
Phase 2 Recruiting
NCT06298084 2024-03-29
ICARUSBREAST02
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting